Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferasirox - Novartis

Drug Profile

Deferasirox - Novartis

Alternative Names: CGP-72670; Deferasirox; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; University Hospital Grenoble
  • Class Antianaemics; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes; Thalassaemia
  • Discontinued Malaria

Most Recent Events

  • 23 Jul 2019 Novartis completes a phase III extension study for Iron overload in Italy, Austria and Greece (PO) (NCT02720536)
  • 13 Jun 2019 Efficacy and adverse events data from a phase II trial in Iron overload (In children, In adolescents) presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 01 Dec 2018 Safety aand efficacy data from the phase II TELESTO trial in myelodysplastic syndromes presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top